S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
NYSEAMERICAN:ATNM

Actinium Pharmaceuticals - ATNM Stock Forecast, Price & News

$7.38
+0.18 (+2.50%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.11
$7.63
50-Day Range
N/A
52-Week Range
$4.41
$9.21
Volume
134,650 shs
Average Volume
380,486 shs
Market Capitalization
$185.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.50

Actinium Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
259.1% Upside
$26.50 Price Target
Short Interest
Healthy
1.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Actinium Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.14) to ($1.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

ATNM stock logo

About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ATNM Stock News Headlines

ATNM Actinium Pharmaceuticals, Inc.
See More Headlines
Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ATNM Company Calendar

Last Earnings
8/12/2022
Today
10/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:ATNM
CIK
N/A
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.50
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+259.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-22,220,000.00
Net Margins
-2,165.56%
Pretax Margin
-2,165.56%

Debt

Sales & Book Value

Annual Sales
$1.14 million
Book Value
$3.50 per share

Miscellaneous

Free Float
21,745,000
Market Cap
$185.87 million
Optionable
Optionable
Beta
0.48

Key Executives

  • Mr. Sandesh C. Seth M.B.A. (Age 58)
    M.S., MBA, Chairman & CEO
    Comp: $1.04M
  • Mr. Steven O'Loughlin BS (Age 36)
    CFO & Corp. Sec.
    Comp: $520k
  • Dr. Paul Diamond Esq.
    Ph.D., VP of Patent & Legal Counsel
  • Dr. David Gould
    Sr. VP of Corp. Devel. & Corp. Affairs
  • Dr. Bernie Cunningham
    Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management
  • Dr. Qing Liang
    VP & Head of Radiation Sciences
  • Dr. Robert N. Daly M.S.
    Ph.D., VP & Head of Clinical Operations
  • Dr. Mamata Gokhale
    VP & Global Head of Regulatory Affairs
  • Dr. Avinash Desai M.D.
    Chief Medical Officer
  • Dr. Arun Swaminathan Ph.D.
    Chief Bus. & Commercial Officer













ATNM Stock - Frequently Asked Questions

Should I buy or sell Actinium Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATNM shares.
View ATNM analyst ratings
or view top-rated stocks.

What is Actinium Pharmaceuticals' stock price forecast for 2022?

4 brokers have issued 1 year price targets for Actinium Pharmaceuticals' shares. Their ATNM share price forecasts range from $16.00 to $45.00. On average, they expect the company's share price to reach $26.50 in the next twelve months. This suggests a possible upside of 259.1% from the stock's current price.
View analysts price targets for ATNM
or view top-rated stocks among Wall Street analysts.

How have ATNM shares performed in 2022?

Actinium Pharmaceuticals' stock was trading at $6.05 at the beginning of 2022. Since then, ATNM shares have increased by 22.0% and is now trading at $7.38.
View the best growth stocks for 2022 here
.

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a decrease in short interest in September. As of September 15th, there was short interest totaling 352,500 shares, a decrease of 10.2% from the August 31st total of 392,700 shares. Based on an average trading volume of 139,200 shares, the short-interest ratio is presently 2.5 days.
View Actinium Pharmaceuticals' Short Interest
.

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) issued its earnings results on Friday, August, 12th. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.10. The biotechnology company earned $0.05 million during the quarter, compared to analysts' expectations of $1.85 million. Actinium Pharmaceuticals had a negative net margin of 2,165.56% and a negative trailing twelve-month return on equity of 32.48%.

When did Actinium Pharmaceuticals' stock split?

Actinium Pharmaceuticals shares reverse split on the morning of Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO).

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $7.38.

How much money does Actinium Pharmaceuticals make?

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) has a market capitalization of $185.87 million and generates $1.14 million in revenue each year.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The official website for the company is www.actiniumpharmaceuticals.com. The biotechnology company can be reached via phone at (646) 677-3870 or via email at investorrelations@actiniumpharma.com.

This page (NYSEAMERICAN:ATNM) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.